Nebraska Administrative Code
Topic - HEALTH AND HUMAN SERVICES SYSTEM
Title 181 - SPECIAL HEALTH PROGRAMS
Chapter 8 - NONSURGICAL PHARMACEUTICAL GENDER ALTERING TREATMENTS
Section 181-8-012 - PATIENT INFORMED CONSENT FOR CROSS-SEX HORMONE TREATMENT
Current through September 17, 2024
A patient consent form must be obtained by the prescribing practitioner and include the following, in addition to information otherwise required in a consent form:
(A) Discussion of appropriateness of care has taken place;
(B) All the known side effects of cross-sex hormone, the risks associated with taking them and the risks associated with discontinuing the treatment including, but not limited to, long-term effects on cardiovascular and cerebrovascular systems, metabolic disorders, increased risk of cancer, bone density, brain development, impact on fertility, sexual side effects including, but not limited to, loss of sexual gratification, and effects upon physical growth and development;
(C) List of alternatives to treatment including, but not limited to, social, behavioral, and physical alternatives, and that these alternatives have been discussed with the patient and parent or legal guardian or the patient, if the patient is an emancipated minor;
(D) Signed consent of a parent or legal guardian or the signed consent of the patient, if the patient is an emancipated minor;
(E) When the patient is an unemancipated minor, patient assent to treatment; and
(F) Whether the medication is being prescribed for off-label use or otherwise not approved by the Food and Drug Administration.
